NEW YORK, July 24, 2017 /PRNewswire/ --
If you want a Stock Review on VRX, PTN, AMAG, or IDXX then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. Pre-market today, DailyStockTracker.com has issued research reports on Valeant Pharmaceuticals International Inc. (NYSE: VRX), Palatin Technologies Inc. (NYSEMKT: PTN), AMAG Pharmaceuticals Inc. (NASDAQ:
Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s shares recorded a trading volume of 10.08 million shares last Friday. The stock finished the trading session 0.57% lower at $17.50. The Company's shares have advanced 27.92% in the last one month, 105.64% over the previous three months, and 20.52% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 20.42% and 18.23%, respectively. Furthermore, shares of Valeant Pharma, which operates as a pharmaceutical and medical device company worldwide, have a Relative Strength Index (RSI) of 65.45.
On July 17th, 2017, Valeant Pharma announced that certain affiliates of it have entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. (the "Fund"). Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited. Access our complete research report on VRX for free at:
On Friday, Cranbury, New Jersey-based Palatin Technologies Inc.'s stock ended the session 1.79% higher at $0.45. A total volume of 828,876 shares was traded. The Company's shares have gained 25.00% in the last one month and 22.52% over the previous three months. The stock is trading 12.85% above its 50-day moving average and 1.25% above its 200-day moving average. Moreover, shares of Palatin Technologies, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have an RSI of 71.20. The complimentary research report on PTN can be downloaded at:
Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc.'s stock ended the day 1.05% higher at $19.30 with a total trading volume of 320,351 shares. The Company's shares have gained 8.73% in the last month. The stock is trading 4.88% above its 50-day moving average. Additionally, shares of AMAG Pharma, which manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the US, have an RSI of 55.00.
On July 20th, 2017, AMAG Pharma announced that its Q2 2017 financial results will be released on August 03rd, 2017, before the US financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results and provide an update on recent corporate developments. The webcast, with slides, will be accessible under the Investors section of the Company's website. Register for free on DailyStockTracker.com and get access to the latest report on AMAG at:
Shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. recorded a trading volume of 357,590 shares. The stock ended Friday's session 0.40% lower at $166.62. The Company's shares have gained 0.01% in the last month, 4.71% over the previous three months, and 42.08% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.28% and 19.10%, respectively. Furthermore, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, have an RSI of 56.16.
On July 17th, 2017, IDEXX Labs announced the election of Stuart M. Essig as a member of the Company's Board of Directors, effective July 12th, 2017. In connection with Dr. Essig's election, the Board also increased its size from eight to nine members, effective on that same day. Download your free research report on IDXX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207) 331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All